Rotavirus W179-9 vaccine - Merck & Co

Drug Profile

Rotavirus W179-9 vaccine - Merck & Co

Alternative Names: Pentavalent human-bovine reassortant rotavirus vaccine - Merck; RotaTeq; Rotavirus vaccine, live, oral, pentavalent; SUB 25745; V260; W179-9

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Banyu; Merck & Co
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections

Most Recent Events

  • 02 Aug 2017 No recent reports on development identified - Phase-III for Rotavirus infections (In infants, Prevention) in China (PO)
  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 01 Jun 2015 Merck completes a phase III trial for Rotavirus infections (Prevention, In infants) in China (NCT02062385)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top